The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Few cases of breast and colorectal cancers should strong membranous positivity. Remaining malignancies were negative.
Breast, colorectal, cervical, renal and urothelial cancers showed moderate to strong membranous and cytoplasmic positivity. Remaining malignancies were generally weakly stained or negative.
Malignant cells were in most cases negative. Cases of ductal carcinoma of breast displayed strong cytoplasmic and membranous immunoreactivity. Few cases of urothelial and colorectal cancers showed moderate cytoplasmic or membranous positivity.
Validation
Two (or more) antibodies yielding partly similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
